Institutional investors purchased a net $475.4 thousand shares of RGEN during the quarter ended March 2015 and now own 91.79% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
TAMRO CAPITAL PARTNERS LLC Bought 530.7 Thousand shares of Repligen Corp
PALISADE CAPITAL MANAGEMENT LLC Bought 372.7 Thousand shares of Repligen Corp